HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeoStrata patent suit

This article was originally published in The Rose Sheet

Executive Summary

Wilmington, Del. federal court rules that Valeant Pharmaceticals willfully infringed two patents held by TriStrata Technology, a subsidiary of NeoStrata, firm announces Nov. 25. Patents cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances." Jury verdict permits treble damages, TriStrata notes. Firm also filed a motion for permanent injunction Nov. 25 to prohibit the sale of infringing products, which include Valeant's Glyquin lines. TriStrata still has a lawsuit pending against Valeant related to another product, and also has filed suit against Mary Kay and BeautiControl. Chanel, Clarins and L'Oréal are among other companies that have been the targets of TriStrata patent infringement suits (1"The Rose Sheet" Aug. 30, 1999, p. 6)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS011716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel